People with Relapsing-Remitting MS try subcutaneous ocrelizumab at their clinic

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study collects patient-reported satisfaction with subcutaneous ocrelizumab in adults with relapsing-remitting MS who are starting SC treatment, switching from IV to SC, or moving from another DMT to SC. It uses routine clinical practice decisions rather than experimental interventions. Participants complete a patient-reported outcome questionnaire (TASQ) to gauge satisfaction. The study does not randomize treatments or compare against a control group. Data will reflect real-world experiences in eligible European clinical settings.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Diagnosis of RRMS according to the revised McDonald criteria (2017 or 2024 revisions).
* Initiation of ocrelizumab s.c in accordance with routine clinical practice and local prescribing information.
* The decision to initiate ocrelizumab s.c. has been made by the treating physician prior to and independently of study participation.
* Willingness to complete the patient-reported outcome questionnaire TASQ, where applicable.

Exclusion Criteria:

* Participation in any clinical study involving disease modifying therapies for multiple sclerosis during the study period or at the time of enrollment.
* Prior treatment with rituximab.
* Contraindications to ocrelizumab as per the local prescribing information.
* Severe psychiatric or cognitive impairment that, in the opinion of the treating physician, would preclude informed consent, reliable participation in the study, or completion of patient-reported outcomes.
* Any condition which, in the opinion of the treating physician, would interfere with participation in the study or the interpretation of study results.
* For participants participating in a Market Research and Patient Support Program (MAP), inclusion is permitted only when a cross-reference to the unique MAP patient identifier is available.

Where it's running

• Nemocnice Pardubickeho kraje, a.s., Pardubicka nemocnice
  Pardubice, Pardubice Region, Czechia Recruiting
• University Medical Centre
  Ljubljana, Slovenia Recruiting

Study contacts

• Study coordinator: Reference Study ID Number: MN46738 https://forpatients.roche.com/ No attachments to email below.
• Email: global-roche-genentech-trials@gene.com
• Phone: 888-662-6728

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Examining personalized treatment for multiple sclerosis with rituximab and ocrelizumab

  This study is testing whether measuring the levels of two different medications, rituximab and ocrelizumab, can help doctors personalize treatment for people with relapsing-remitting multiple sclerosis who are just starting therapy.

  Recruiting Haukeland University Hospital · Bergen, Vestland · NCT06663111

• Comparing Rituximab and Ocrelizumab for Relapsing-Remitting Multiple Sclerosis

  This study is testing whether rituximab can work just as well as ocrelizumab in helping people with relapsing-remitting multiple sclerosis manage their symptoms over two years.

  Recruiting at 9 sites Phase 3 Rennes University Hospital · Lyon, Bron and 22 other locations · NCT05758831

• Terfenadine added to standard MS therapy in relapsing MS

  This study tests whether adding terfenadine to usual MS treatment is safe and may help reduce disease activity in adults with relapsing-remitting MS.

  Recruiting Phase 2 Tongji Hospital · Wuhan, Hubei · NCT07827716

• Comparing Ofatumumab vs Ocrelizumab in Real-World MS Care

  This real-world study tests whether ofatumumab works differently from ocrelizumab for people with multiple sclerosis.

  Recruiting Novartis · East Hanover, New Jersey · NCT07779460

• Ocrelizumab given under the skin after switching from another anti-CD20 therapy

  This study tests a subcutaneous form of ocrelizumab mixed with rHuPH20 in people with relapsing or primary progressive MS who are switching from another anti-CD20 treatment.

  Recruiting at 8 sites Phase 4 Genentech, Inc. · Birmingham, Alabama and 7 other locations · NCT07609719

• HiHat: Rituximab Followed by Cladribine in Relapsing-Remitting MS

  This trial tests whether giving rituximab and then cladribine in sequence is safe and doable for people with relapsing-remitting MS.

  Recruiting at 3 sites Phase 2 Uppsala University · Falun and 3 other locations · NCT07517185

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.